Here’s what you should know:
1. Orthotaxy is in the midst of developing a differentiated robotic-assisted surgery solution.
2. The proprietary technology is in early-stage development and will address total and partial knee replacements.
3. Johnson & Johnson will leverage the technology to develop cost-effective, time-efficient, user-friendly orthopedic offerings.
4. J&J’s DePuy Synthes Company Group Chairman Ciro Rӧmer said, “Our goal is to bring to market a robotic-assisted surgery technology that is an integral part of a comprehensive orthopaedics platform, delivering value to patients, physicians and healthcare providers across the episode of care.”
More articles on supply chain:
5 key observations on NJ ASC landscape post-‘One-Room Bill”
To prevent the spread of norovirus at the Olympics, athletes told to fist-bump, not shake hands: 4 things to know
Partner at Seaside Surgery Center receives board certification — 4 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.